Indiva Ltd V.NDVA.H

NDVA Hits Another 52-Week Low of C$ 0.075

[davgro]

General negative sentiment in the cannabis sector is again weighing on the NDVA stock price.  A new 52-week low on higher than normal daily volume.

Most cannabis stocks are setting new 52-week lows as recent earnings reports have shown that revenue is dropping each quarter.  HEXO and AYR.A both recently reported disappointing quarters for revenue and the share price was punished.  There is a contagion effect in play that is depressing the share price on any companies in the pot sector.  No one is immune.

The April earnings report for NDVA will be critical.  If they disappoint again then I anticipate the share price will continue its slow decline.  I wouldn't even consider averaging down at this point until I see the next financials.

[QCINDIVALUVIN]

What would be considered a disappointment? I think it should be between 10 and 11m. Depressing SP indeed...

[davgro]

I wish I could be as optimistic as you but I anticipate gross revenue to be under $9M for 2022 Q4.  Most Canadian LPs are reporting quarter over quarter declines in revenue and I don't expect NDVA to be the exception. I think that current share price reflects NDVA investors expectations.  Q4 2022 earnings will tell the true story along with management's 2023 guidance. If you

[caretired1]

Same here.  Maybe I'm gun shy based on past results.  Q3 was net revenue 8.1 but that was with the BC strike and OCS shutdown for a couple of weeks.  As well lozenges and pearls were in market all of Q4.  Given all that, I still don't think they get to 10 million.  I sure hope they are over 9.  Q1 should hold against the prior year comparable given lozenges